search results for

refine results

sort by


result type


Press Releases

Unusual activity: Bullish buying in PHM & INTC

“Fast Money Halftime Report” traders Jon and Pete Najarian discuss unusual options activity in PulteGroup and Intel.


Dow Transports join other averages at record highs

Dow Transports hits record territory yet again, CNBC's Dominic Chu reports.


Bethune: Optimistic Trump will be better for business

CNBC Contributor Gordon Bethune, former Continental Airlines chairman and CEO, shares his bull case for the airlines, as well whether President-elect Donald Trump will be good for business.


Shiller: It's not a good time, but I'm not saying panic

Robert Shiller, Yale University professor of economics, discusses why the current market environment is reminiscent of the stock market crash of 1929, and how Trump's presidency can bring about a different outcome.


Trading the Trump rally: What's next for the markets?

Adam Parker, Morgan Stanley chief U.S. equity strategist, the “Fast Money Halftime Report” traders and Kourtney Gibson, Loop Capital president, weigh in on the Trump rally, and whether it will continue.


Unusual activity: Bullish buying in TWTR & MSFT

“Fast Money Halftime Report” traders Jon and Pete Najarian discuss unusual options activity in Twitter and Microsoft.


BofA: Risk/reward more important than absolute targets

Savita Subramanian, BofA Merrill Lynch head of U.S. equity & quantitative strategy, shares her 2017 outlook.


Starbucks plans to open 12,000 stores by 2021

The “Fast Money Halftime Report” traders discuss the trade on Starbucks as the company lays out its expansion plans.


Sonnenfeld: Trump is not a theorist, he's a pragmatist

CNBC contributor Jeff Sonnenfeld, Yale School of Management, weighs in on the uncertainty surrounding Donald Trump's presidential plans, and what to make of it.


Meekins: Don't read much into Trump drug pricing comments

Chris Meekins, FBR research analyst, discusses three reasons to ignore Donald Trump's comments against the current drug prices.